Akshaya Chandrasekaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akshaya Chandrasekaran has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Juan Andres Melendez
College of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY 12203, USA
3 shared publications - Sara A. Brenner
College of Nanoscale Science, Nanobioscience Constellation, State University of New York (SUNY) Polytechnic Institute, Albany, New York, 12203
2 shared publications - Adam J. Friedman
Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
1 shared publication Barbara A. Miller
Pediatrics and Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
1 shared publicationGary A. Roth
SUNY Polytechnic Institute, Colleges of Nanoscale Science and Engineering, 257 Fuller Road, Albany, NY 12203, United States
1 shared publicationJ. Andres Melendez
Nanobioscience Constellation, Colleges of Nanoscale Science and Engineering, SUNY Polytechnic Institute, State University of New York
1 shared publication
Latest Publications
- Open Access
- 13 September 2021
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (11) , 2117-2128
Synthetic Lethality in Ovarian Cancer
Ovarian cancers include several distinct malignancies which differ with respect to clinicopathologic features and prognosis. High-grade serous cancer is the most common histologic subtype and accounts for most ovarian cancer–related deaths. High-grade serous ovarian cancer (HGSOC) is treated with surgery and platinum-based chemotherapy, but most patients relapse and succumb to chemoresistant disease. The genetic concept of synthetic lethality, in which the synergy of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to overcome chemoresistance in ovarian cancer. Recent progress in understanding the genomic architecture and hereditary drivers of ovarian cancer has shown potential for synthetic lethality strategies designed around homologous DNA repair. Clinical trials have validated high response rates for PARP inhibitors in patients with BRCA1 or BRCA2 mutations. Here we discuss the biological rationale behind targeting BRCA–PARP synthetic lethality based on genetic context in ovarian cancer and how this approach is being assessed in the clinic. Applying the concept of synthetic lethality to target non–BRCA-mutant cancers is an ongoing challenge, and we discuss novel approaches to target ovarian cancer using synthetic lethality in combination with and beyond PARP inhibitors. This review will also describe obstacles for synthetic lethality in ovarian cancer and new opportunities to develop potent targeted drugs for patients with ovarian cancer.
- 13 September 2021
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (11) , 2117-2128
Open AccessSynthetic Lethality in Ovarian Cancer
Ovarian cancers include several distinct malignancies which differ with respect to clinicopathologic features and prognosis. High-grade serous cancer is the most common histologic subtype and accounts for most ovarian cancer–related deaths. High-grade serous ovarian cancer (HGSOC) is treated with surgery and platinum-based chemotherapy, but most patients relapse and succumb to chemoresistant disease. The genetic concept of synthetic lethality, in which the synergy of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to overcome chemoresistance in ovarian cancer. Recent progress in understanding the genomic architecture and hereditary drivers of ovarian cancer has shown potential for synthetic lethality strategies designed around homologous DNA repair. Clinical trials have validated high response rates for PARP inhibitors in patients with BRCA1 or BRCA2 mutations. Here we discuss the biological rationale behind targeting BRCA–PARP synthetic lethality based on genetic context in ovarian cancer and how this approach is being assessed in the clinic. Applying the concept of synthetic lethality to target non–BRCA-mutant cancers is an ongoing challenge, and we discuss novel approaches to target ovarian cancer using synthetic lethality in combination with and beyond PARP inhibitors. This review will also describe obstacles for synthetic lethality in ovarian cancer and new opportunities to develop potent targeted drugs for patients with ovarian cancer.
- Open Access
- 1 April 2017
- Published by Elsevier in Redox Biology
- Vol. 11, 91-102
Redox control of senescence and age-related disease
- 1 April 2017
- Published by Elsevier in Redox Biology
- Vol. 11, 91-102
Open AccessRedox control of senescence and age-related disease
- 1 July 2016
- Published by Elsevier in NanoImpact
- Vol. 3-4, 12-21
Relative quantitation of metal oxide nanoparticles in a cutaneous exposure model using enhanced darkfield microscopy and hyperspectral mapping
- 1 July 2016
- Published by Elsevier in NanoImpact
- Vol. 3-4, 12-21
Relative quantitation of metal oxide nanoparticles in a cutaneous exposure model using enhanced darkfield microscopy and hyperspectral mapping
- Open Access
- 1 February 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (8) , 3871-3881
Francisella tularensis Catalase Restricts Immune Function by Impairing TRPM2 Channel Activity
- 1 February 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (8) , 3871-3881
Open AccessFrancisella tularensis Catalase Restricts Immune Function by Impairing TRPM2 Channel Activity
- 1 December 2015
- Published by Elsevier in Toxicology Letters
- Vol. 239 (3) , 205-215
Comparative analysis of redox and inflammatory properties of pristine nanomaterials and commonly used semiconductor manufacturing nano-abrasives
- 1 December 2015
- Published by Elsevier in Toxicology Letters
- Vol. 239 (3) , 205-215
Comparative analysis of redox and inflammatory properties of pristine nanomaterials and commonly used semiconductor manufacturing nano-abrasives
- 1 September 2014
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 74, 99-107
Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression
- 1 September 2014
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 74, 99-107
Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression